Kamada Announces Amendment to GLASSIA® License Agreement with Takeda

  • Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product’s US Biologics License Application (BLA) to Takeda; Expected to Occur by End of 2021
  • Kamada to Receive from Takeda a Payment of $2 Million for the BLA Transfer
  • Final Sales-Based Milestone Payment of $5 Million Due to Kamada under the License Agreement was Accelerated
  • No Other Material Changes to the GLASSIA License Agreement Between Kamada and Takeda
  • Kamada Continues to Distribute GLASSIA Outside of Takeda’s Territories and Invests in the Alpha-1
    Antitrypsin Deficiency Field Through Continued Development of the Inhaled AAT Product, Currently in a Phase III Clinical Study

REHOVOT, Israel, April 07, 2021 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced an amendment to the GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] license agreement with Takeda. Pursuant to the amendment, upon completion of the transition of GLASSIA manufacturing to Takeda, expected by the end of 2021, Kamada will transfer to Takeda the GLASSIA U.S. Biologics License Application (BLA). In consideration for the BLA transfer, Kamada will receive a $2 million payment from Takeda. In addition, the payment by Takeda of the final sales-based milestone of $5 million due to Kamada under the license agreement was accelerated and the Company anticipates it will be able to recognize this milestone during 2021. The parties have agreed to continue to share product related information and data following the BLA transfer. There are no other material changes to the existing GLASSIA license agreement.  

“Based on the planned transition of GLASSIA manufacturing to Takeda later this year, and its continued distribution of the product in the U.S., the transfer of the BLA to Takeda is a prudent next step,” said Amir London, Kamada’s Chief Executive Officer. “Kamada, as the product’s innovator, continues the registration and distribution of GLASSIA in countries, outside of the named territories of the U.S., Canada, Australia and New Zealand retained by Takeda, and invests in the Alpha-1 Antitrypsin Deficiency field through continued development of our proprietary Inhaled AAT product for which we are currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 study.”

GLASSIA was developed by Kamada, and the product’s BLA was approved by the U.S. Food and Drug Administration in 2010 as the first liquid, ready-to-use, intravenous plasma-derived augmentation therapy to treat Alpha-1 Antitrypsin deficiency.

As previously reported, Kamada expects to receive approximately $25 million in product revenues from the supply of GLASSIA to Takeda in 2021, and based on the agreement with Takeda, upon the initiation of sales of GLASSIA manufactured by Takeda, Kamada will receive royalty payments at a rate of 12% of net sales through August 2025 and at a rate of 6% thereafter until 2040, with a minimum of $5 million annually for each of the years from 2022 to 2040. Although the transition of the agreement to its royalties phase will result in a reduction of Kamada’s revenue from Takeda, based on current GLASSIA sales in the U.S. and forecasted future growth, Kamada anticipates receiving royalties from Takeda in the range of $10 million to $20 million per year from 2022 to 2040.

About Kamada

Kamada Ltd. (the “Company”) is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company’s two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited (“Takeda”) and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: (1) the transfer of the BLA to Takeda to occur by the end of 2021; (2) Kamada’s anticipation to be able to recognize the $5 million sales milestone during 2021; (3) the parties’ agreement to share product related information and data following the BLA transfer; (4) statements regarding Kamada’s continued registration and distribution of GLASSIA outside Takeda’s territories, and investment in the Alpha-1 Antitrypsin Deficiency field through development of the Inhaled AAT product, currently in a Phase III clinical study; (5) Kamada’s expectation of approximately $25 million in product revenues from the supply of GLASSIA to Takeda in 2021; and (6) Kamada’s expectation of receiving royalties from Takeda in the range of $10 million to $20 million per year from 2022 to 2040. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, market demand for GLASSIA which affects royalties derived from GLASSIA by Kamada, delay or denial in the U.S. FDA approval process for Inhaled AAT products; Kamada’s ability to conduct clinical trials in light of restrictions during the COVID-19 pandemic, Kamada’s ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, prevailing market conditions and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:

Chaime Orlev
Chief Financial Officer
[email protected]

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]



Tonix Pharmaceuticals to Present at Needham Virtual Healthcare Conference

CHATHAM, N.J., April 07, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company overview during the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:00 a.m. ET.

Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the Needham conference coordinator. A webcast of the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com.

Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the third quarter of 20212 and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix’s lead vaccine candidate, TNX-18003, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8013, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.


1

TNX-102 SL is an investigational new drug and has not been approved for any indication.


2

Pending agreement from FDA on statistical analysis plan.


3

TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2021, and periodic reports filed with the SEC on or after the date thereof. All Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
[email protected]
(862) 904-8182

Olipriya Das, Ph.D. (media)
Russo Partners
[email protected]
(646) 942-5588

Peter Vozzo (investors)
Westwicke/ICR
[email protected]
(443) 213-0505



Motorsport Games Welcomes Gérard Neveu as Motorsports Advisor

Industry Expert Who Staged Largest Virtual Racing Event in History to Enhance Company’s Authentic Connection to the World of Motorsports

MIAMI, April 07, 2021 (GLOBE NEWSWIRE) — Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games”), leading racing game developer, publisher and esports ecosystem provider of official motorsport racing series throughout the world, today announced that highly experienced motorsport promoter Gérard Neveu will serve as Motorsport Games’ Motorsports Advisor, acting as the primary conduit between Motorsport Games and the world’s motorsport series and larger motorsport industry as a whole. Neveu will be responsible for developing, enhancing and executing projects and agreements between Motorsport Games’ esport business and the motorsport industry, while ensuring maximum authenticity across Motorsport Games’ virtual offerings along the way.

Well known and highly respected throughout the motorsport world, Neveu comes to Motorsport Games after a successful 10-year stint as CEO of the FIA World Endurance Championship (WEC). In 2020, together with Motorsport Games and the Automobile Club de l’Ouest (ACO), he staged the blockbuster 24 Hours of Le Mans Virtual esports race that garnered TV audiences of 14.2 million and over 131 million digital impressions during the event. The largest virtual racing event in history, the 24 Hours of Le Mans Virtual connected 200 of the best-known real world and esports racing drivers across 30 different countries for 25 hours of live production.

“With Gérard’s extensive experience, we are certain he will ensure our brand remains genuine and continues to resonate and grow within the industry, all while creating world-class entertainment and content,” said Dmitry Kozko, CEO of Motorsport Games. “At Motorsport Games, motorsport isn’t just part of our brand, it’s in our DNA. Industry experts like Gérard enhance our authenticity and ensure we are thinking big, creating the most exciting new business opportunities for our Company and for our fans.”

“Motorsport Games is becoming the go-to leader in the virtual racing space – I’m excited to work with the team to build upon the company’s existing major live events and continue to help spread the joy of virtual racing with fans around the world,” added GérardNeveu. “Virtual racing and esports have become major parts of the future within the world of motorsport and I’m honored to get to be a part of the phenomenon. By connecting real life motorsports with virtual racing events, we can create a whole new community that goes beyond just watching on TV, to actually participating in world class racing events.”

Motorsport Games has gained a reputation of excellence and has quickly evolved into the partner of choice for many racing series throughout the world. Motorsport Games has licenses to develop and publish games and esports based on NASCAR, the 24 Hours of Le Mans and the British Touring Car Championship. In addition to its plans to acquire rFactor2 and Studio 397, the company has recently announced the acquisition of KartKraft, the leading kart racing simulator, and its plans to purchase mobile games developer Digital Tales.

About Motorsport Games:

Motorsport Games, a Motorsport Network company, combines innovative and engaging video games with exciting esports competitions and content for racing fans and gamers around the globe. The Company is the officially licensed video game developer and publisher for iconic motorsport racing series including NASCAR, 24 Hours of Le Mans and the British Touring Car Championship (“BTCC”), as well as other racing games. Motorsport Games is an award-winning esports partner of choice for 24 Hours of Le Mans, Formula E, BTCC, the FIA World Rallycross Championship and the eNASCAR Heat Pro League, among others.

For more information about Motorsport Games visit: www.motorsportgames.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Motorsport Games and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to whether Motorsport Games will achieve its goals in connection with making the connection between esports and real motorsports. Additional examples of such risks and uncertainties include, but are not limited to (i) Motorsport Games’ ability (or inability) to maintain existing, and secure additional, licenses and contracts with the sports series; (ii) Motorsport Games’ ability to successfully manage and integrate any joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on Motorsport Games’ business; (vi) the risk that changes in consumer behavior could adversely affect Motorsport Games’ business; (vii) Motorsport Games’ ability to protect its intellectual property; and (viii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in Motorsport Games’ filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2020 to be filed with the SEC. Motorsport Games anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Motorsport Games assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Motorsport Games’ plans and expectations as of any subsequent date.

Press:


[email protected]

Investors:

Ashley DeSimone
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/217202fb-ba31-4ab5-998e-0b38881d2428



Anavex Life Sciences Announces Participation at Upcoming World EPA – Evidence, Pricing and Access – Congress 2021

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, “Establishing Mutually Beneficial Collaborations,” at the World EPA Congress 2021 event on Thursday, April 15th at 8:55 a.m. EDT (14:55 CET).

World EPA – Evidence, Pricing and Access – Congress 2021 is the world’s leading healthcare evidence, pricing and access congress and the host of the world’s very first Community-based stakeholder collaboration zone. The virtual congress will be held, April 13th – April 15th, 2021.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease and a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter,Facebook and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: [email protected]

Investors:

Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: [email protected]



Homes For Heroes Breaks Ground On ATCO Edmonton Veterans Village

EDMONTON, Alberta, April 07, 2021 (GLOBE NEWSWIRE) — Homes For Heroes Foundation is excited to announce that they have started construction on the Edmonton ATCO Veterans Village scheduled to open October 1st, 2021. Homes For Heroes Foundation is a Canadian registered charity, building tiny home villages, with wrap around social services, to help Veterans reintegrate to civilian life. Home For Heroes Foundation mission is to end the issue of Veteran homelessness in Canada. The Edmonton ATCO Veterans Village will consist of 20 tiny homes, a resources center, counselors office, a community recreation space, and community gardens.

“This an exciting time for our charity, our partners, and our supporters. Our Calgary village has been operating for eighteen months with amazing results and now we are well on our way to getting the Edmonton ATCO Veterans Village built. The citizens of Edmonton have shown much love and respect for our charity and those that served, and we appreciate all the support,” stated David Howard, CEO, Homes For Heroes Foundation.

“Projects like these – whether in Edmonton or in other communities – play a vital role in helping to reduce Veteran homelessness across the country. I’ve seen the impact they have on the Veterans who come through them, and I’m proud we’re able to work alongside groups like Homes For Heroes who are so committed to supporting folks who’ve served Canada in uniform at a time when they need it most,”
noted The Honourable Lawrence MacAulay, Minister of Veterans Affairs and Associate Minister of National Defence.

“It’s good news to see the ground-breaking on this amazing facility that is giving homes to the women and men who put their lives on the line for our country. Homes For Heroes continues to provide support and care for our veterans, and we are grateful for their service.” stated Jason Kenney, Premier of Alberta.

“The City of Edmonton is proud to have taken a leadership role in the goal to end homelessness among Veterans through this partnership with the Homes For Heroes Foundation. The City’s support of this Veterans village will ensure that those who proudly served and sacrificed for our country have the stability and dignity they deserve and need,” said Don Iveson, Mayor of Edmonton.

The Homes For Heroes Foundation was developed in response to the growing number of Canadian Veterans who are facing a crisis as they return to civilian live and find themselves on a path to homelessness. More than 5,000 Veterans are homeless and living on the streets in Canada. These Veterans put their lives on the line for the freedoms all Canadians enjoy and Homes For Heroes Foundation plans to build villages across Canada to help these brave women and men reintegrate to civilian life.

“The women and men who serve in Canada’s military give so much on our country’s behalf and deserve our community’s support — especially in their post-service years. We have a long history of working closely with our military and the people of ATCO are humbled to be part of a community-driven approach to support our heroes and remind them that their contributions are not forgotten,” said Nancy Southern, Chair & Chief Executive Officer, ATCO

“Our team has been working with Homes For Heroes over the past several months planning the Edmonton project and are excited to kick off construction. PCL has been a partner on the development and construction with Homes For Heroes since 2018 with the successful opening of the first village in Calgary. In partnership with ATCO and our other trade contractors, we are proud to be part of the Homes For Heroes village in Edmonton which will support their mission to integrate our homeless Canadian military veterans into the community.” stated Jason Portas, Vice President and District Manager at PCL Construction.

“Homes for Heroes offer accommodation, comradeship and the highest standards of care in recognition of our homeless veterans’ loyal service to the nation. We want to give them something they can stay in, call it their own, and then socialize and re-integrate at their own pace. Any former soldier, sailor and aviator who is facing homelessness deserves Canada’s support,” declared Stephen Lacroix, Brigadier-General (retired) and Honorary Chair Homes For Heroes Foundation.

Homes For Heroes endorses the concepts of “Housing First” and “Harm Reduction” providing wrap-around service delivery through a team-based, collaborative case management approach.  Homes For Heroes partners with Veterans Affairs and local social service agencies to sponsor veterans into the Homes For Heroes program and the tenants are offered a structured, yet nurturing, environment required to ensure positive emotional, psychological, and physical development.

“There is still a lot of work to be done to end the issue of Veteran homeless, but the Edmonton ATCO Veterans village is another step in the right direction. We congratulate and thank all the Canadian charities who are dedicated to helping the women and men who proudly served Canada. Together we will end the cycle of Veteran homelessness.” stated David Howard, CEO, Homes For Heroes Foundation.

Further information on the Homes For Heroes Foundation can be found at www.h4hf.ca                                        

Media Contact

David Howard
CEO
Homes For Heroes Foundation
[email protected] or 403-452-0888

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/83f5f87a-f0e8-45ff-a94f-86cb79364e26
https://www.globenewswire.com/NewsRoom/AttachmentNg/3d48ec23-9d64-4f71-a1ad-f44914012bb6



Avolon Ends First Quarter With ~$7bn of Total Liquidity

Avolon Ends First Quarter With ~$7bn of Total Liquidity

DUBLIN–(BUSINESS WIRE)–
Avolon, the international aircraft leasing company, issues an update for the first quarter of 2021 (‘Q1’).

Q1 FLEET METRICS & BUSINESS HIGHLIGHTS

– Executed a total of 31 lease transactions in the quarter comprising new aircraft leases, follow-on leases and lease extensions;

– Entered into Letters of Intent for the placement of 27 owned aircraft;

– Sold 2 aircraft during the quarter;

– Delivered a total of 8 new aircraft to 6 customers and transitioned 3 aircraft to follow-on lessees;

– Ended first quarter with total of 146 airline customers operating in 61 countries;

– Agreed an option to defer 34 single aisle and 3 twin aisle orderbook commitments from the 2022/23 period to 2025 and beyond, and;

– Owned and managed fleet of 578 aircraft at quarter end, with total orders and commitments for 264 fuel-efficient, new technology aircraft.

Q1 STRATEGIC & FINANCIAL HIGHLIGHTS

– Total available liquidity of approximately $7 billion at quarter end;

– Closed a private offering of senior unsecured notes, with an aggregate principal amount of $1.5 billion, and historically low coupon rates of 2.125% and 2.75% for 2026 and 2028 maturities respectively, and;

– Proactively repaid approximately $740 million of secured debt, $470 million of which continues to be available through revolving facilities.

ENDS

About Avolon

Headquartered in Ireland, with offices in the United States, Dubai, Singapore, Hong Kong and Shanghai, Avolon provides aircraft leasing and lease management services. Avolon is 70% owned by an indirect subsidiary of Bohai Leasing Co., Ltd., a public company listed on the Shenzhen Stock Exchange (SLE: 000415) and 30% owned by ORIX Aviation Systems, a subsidiary of ORIX Corporation which is listed on the Tokyo and New York Stock Exchanges (TSE: 8591; NYSE: IX). Avolon is the world’s third largest aircraft leasing business with an owned, managed and committed fleet, as of 31 March 2021 of 842 aircraft.

Website: www.avolon.aero

Twitter: @avolon_aero

Note Regarding Forward-Looking Statements

This document includes forward-looking statements, beliefs or opinions, including statements with respect to Avolon’s business, financial condition, results of operations and plans. These forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond our control and all of which are based on our management’s current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as “believe,” “expects,” “may,” “will,” “could,” “should,” “shall,” “risk,” “intends,” “estimates,” “aims,” “plans,” “predicts,” “continues,” “assumes,” “positioned” or “anticipates” or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. Forward-looking statements may and often do differ materially from actual results. No assurance can be given that such future results will be achieved.

Ross O’Connor

Head of Capital Markets

[email protected]

T: +353 1 231 5818

Emmet Moloney

Head of Communication

[email protected]

T: +353 1 556 4429

Jonathan Neilan

FTI Consulting

[email protected] 

M: +353 86 231 4135

 

KEYWORDS: Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Professional Services Air Transport Finance

MEDIA:

Applied DNA and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program

Applied DNA and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program

– Offers Valuable Real-Time Surveillance of SARS-CoV-2 Mutations and VoCs-

 – Program Powered by Applied DNA’s Mutation-targeted qPCR Assays and NGS Platform –

– Program Data Potentially Relevant to COVID-19 Vaccine and Therapeutics Developers, Precision Medicine –

STONY BROOK & NEW HYDE PARK, N.Y.–(BUSINESS WIRE)–Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and Northwell Health (Northwell) today announced their entry into a pro bono Material Transfer Agreement (MTA) that establishes a real-time surveillance program for the tracking and identification of SARS-CoV-2 mutations and variants of concern (VoCs) in Northwell’s COVID-positive specimens (the “Program”). Under the Program, de-identified positive COVID-19 specimens supplied by Northwell are being screened for SARS-CoV-2 mutations found in currently known VoCs using Applied DNA’s Linea COVID-19 Assay Kit (“Assay Kit”) and Selective Genomic Surveillance (SGS) Mutation Panel. The Program currently has the analysis of over 2,000 samples underway, with early results from approximately 360 samples showing that approximately 80% of specimens tested on the Company’s qPCR assays contain one or more mutations. Data generated from the Program will enable Northwell to make more efficient use of costly and time-consuming next-generation sequencing (NGS) necessary to conclusively identify specific VoCs and their subsequent descendants. Aggregate data from the Program that could influence vaccine or booster design, antibody therapies, or drug development may be monetized by either party under a revenue-share structure. The Program also provides valuable SARS-CoV-2 mutation data to support the continued validation of the Company’s SGS Mutation Panel. An Applied DNA-authored white paper on SGS of SARS-CoV-2 will be available for publication shortly.

The combination of the SGS Mutation Panel and Assay Kit in a prescreening modality is offered for sale to healthcare institutions, healthcare systems, and governmental agencies seeking a cost-effective platform to better understand how, where, and why COVID-19 mutations and VoCs are spreading. Aggregate data obtained by the Company from the Program and other testing partners will be made available to COVID-19 vaccine or therapeutic developers to develop new tools to combat the ever-changing nature of SARS-CoV-2.

“We believe that the combination of our Assay Kit and SGS Mutation Panel as a method of prescreening COVID-19 positive specimens presents a rational approach to the use of nationally constrained next-generation sequencing capacity. The participation of Northwell, New York State’s largest healthcare system and among the largest in the nation, validates our approach that utilizes our newly established SGS Mutation Panel and NGS capabilities,” said Dr. James A. Hayward, president and CEO, Applied DNA. “The ability to identify high-value positive samples containing certain mutations that should be subject to NGS should enable the more efficient discovery and tracking of VoCs that could greatly improve the nation’s ability to track and stay ahead of the variants. If taken up broadly in the U.S., we believe that national NGS resources could be more precisely targeted toward variants of the strongest epidemiological relevance via the use of our SGS Mutation Panel.

“Another top priority with our SGS Mutation Panel is to enable improved diagnostics that may yield improvements in therapeutic outcomes and patient clinical care. As we gather data from the Program and other specimens being run on the SGS Mutation Panel, the incidence rates of specific mutations identified by our qPCR assays and NGS data, when linked to patient outcomes, the pathogenesis of their disease and their response to interventions may provide valuable data for clinical care, vaccine design, booster design and choice of targets for antibody and other therapies,” concluded Dr. Hayward.

“The Applied DNA Sciences approach permits rapid and inexpensive identification of mutations that are concerning in the clinical community, such as the E484K and L452R mutations which may confer resistance to some therapies or specific antibodies,” said Dr. Dwayne Allen Breining, executive director of Northwell Health Labs.

Data generated from the Program may be relevant to:

  1. COVID-19 vaccine manufacturers – Aggregate data from the program may be used by therapeutic manufactures to obtain a large-scale view of the S-gene mutations most commonly circulating in a population. This data may help design next-generation COVID-19 vaccines to address identified common and/or emerging S-gene mutations;
  2. COVID-19 mAB (monoclonal antibody) therapy manufacturers – Some VoCs can cause resistance to one or more of the mAb therapies authorized to treat COVID-19. As mAb therapies lose activity against some of the VOCs, manufacturers of mAb therapies will need to design new antibodies targeting the altered Spike proteins. qPCR-based mutation data and sequencing data developed by Applied DNA’s in-house NGS capacity will be made available to manufacturers;
  3. Precision medicine – Applied DNA will supply aggregate data back to Northwell Health to re-associate the results with the patients who provided the samples with such re-associations potentially yielding unique disease pathogenesis correlated with specific mutations to improve the standard of care based on specific mutations.

Applied DNA’s SGS Mutation Panel is designed to enhance the effectiveness of the limited NGS resource. The Company has developed a Research Use Only (RUO) panel of eight qPCR assays that target the salient mutations that characterize (and in some cases are shared by) the Variants of Concern (VoCs). When used in conjunction with the Company’s Assay Kit, the SGS Mutation Panel currently screens for the following mutations: 69-70del, E484K, N501Y, P681H, S477N, L452R, K417, and N439K with additional relevant mutation targets added as they arise. The qPCR assay-based analysis of SARS-CoV-2 positive samples can quickly, and cost effectively, provide valuable mutation related data points on large numbers of specimens without NGS characterization and also be used to select high-value samples to subject to NGS. The SGS Mutation Panel complements the Assay Kit that is the only EUA RT-PCR assay to target two amplicons in the S gene of SARS-CoV-2, and which experiences S-drop when testing specimens containing the 69-70del mutation, while providing a positive test result due to the unaffected second S gene assay target. Applied DNA’s NGS platform is a high throughput device that can be utilized to sequence up to 200 viral genomes per day.

About the Linea™ COVID-19 Assay Kit and the Linea™ COVID-19 Selective Genomic Surveillance™ (SGS) Mutation Panel

The Linea™ COVID-19 Assay Kit is authorized by FDA EUA for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens, including anterior nasal swabs, self-collected at a healthcare location or collected by a healthcare worker, and nasopharyngeal and oropharyngeal swabs, mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, and bronchoalveolar lavage (BAL) specimens collected by a healthcare worker from individuals who are suspected of COVID-19 by their healthcare provider. The scope of the Linea COVID-19 Assay Kit EUA, as amended, is expressly limited to use consistent with the Instructions for Use by authorized laboratories, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity tests. The EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated or until the EUA’s prior termination or revocation. The diagnostic kit has not been FDA cleared or approved, and the EUA’s limited authorization is only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.

The Linea COVID-19 Selective Genomic Surveillance (SGS) Mutation Panel (the “SGS Panel”) is for Research Use Only (RUO) and shall not be used for clinical diagnostic purposes. The SGS Panel has not been approved or authorized to diagnose, ameliorate and/or detect any disease by any U.S. or international regulatory authority. In addition, all NGS services to be offered by the Company will be for Research Use Only (RUO).

About Northwell Health

Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals, 830 outpatient facilities and more than 16,600 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 76,000 employees – 18,900 nurses and 4,800 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We’re training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Twitter, Instagram and LinkedIn.

About Applied DNA Sciences

Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company’s deep expertise in DNA.

The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW.’

Applied DNA is a member of the Russell Microcap® Index.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, the possibility that the assay kit could become obsolete or have its utility diminished, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s or its partner’s diagnostic candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration (U.S. FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to U.S. FDA, equivalent foreign regulatory agencies and/or the New York State Department of Health, the unknown limited duration of any Emergency Use Authorization (EUA) approval from U.S. FDA, changes in guidances promulgated by the CDC, U.S. FDA and/or CMS relating to COVID-19 surveillance and diagnostic testing, disruptions in the supply of raw materials and supplies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 17, 2020, and Form 10-Q filed on February 11, 2021 and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

For Applied DNA:

Investor contact: Sanjay M. Hurry, Applied DNA Sciences, 917-733-5573, [email protected]

Web:www.adnas.com

Twitter: @APDN

For Northwell Health:

WEB: www.northwell.edu

Twitter: @northwellhealth

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Research Pharmaceutical Oncology Infectious Diseases Hospitals Clinical Trials Science Biotechnology Stem Cells FDA Other Science Health

MEDIA:

Logo
Logo

XL Fleet Electrifying Apex Clean Energy Pickup Fleet

XL Fleet Electrifying Apex Clean Energy Pickup Fleet

Leading clean energy company is electrifying its work truck fleet with XL Fleet plug-in hybrid and hybrid systems on its F-Series pickup trucks

Apex fleet electrification investment will support its commitment to reduce carbon emissions

Vehicles were acquired for Apex by XL Fleet’s Fleet Management Company (FMC) partner Enterprise Fleet Management

BOSTON–(BUSINESS WIRE)–
XL Fleet Corp. (NYSE: XL) (“XL Fleet” or the “Company”), a leader in fleet electrification solutions, and Apex Clean Energy (“Apex”), a leading clean energy company that develops, constructs, and operates utility-scale wind and solar power facilities throughout North America, today announced that XL Fleet is electrifying Apex’s vehicle fleet as part of a comprehensive effort to reduce its carbon emissions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005381/en/

(Photo: Business Wire)

(Photo: Business Wire)

Apex’s first investment in vehicle electrification, the order will provide 19 electrified Ford F-series pickup trucks, including ten plug-in hybrid electric and nine hybrid electric systems for pickups in its service fleet, for delivery in the second quarter of 2021. The strategic mix of hybrid and plug-in hybrid electric vehicles being deployed aligns with Apex’s current sustainability goals and operational requirements, while allowing it to consider expanding its electrification investments as it replaces more vehicles in the future.

XL Fleet’s electrification systems will enable Apex to equip its project teams with a diverse array of cleaner, more fuel-efficient vehicles as Apex installs renewable power generation equipment and facilities throughout North America. Apex is planning to deploy the plug-in hybrid vehicles to its operations employees, who will have access to charging infrastructure being installed at operational wind and solar facilities. The hybrid vehicles are expected to be used by Apex’s on-site construction team, who currently do not have regular access to charging infrastructure and will benefit from the regenerative braking provided by the XL Fleet hybrid system. In the past decade, Apex has commercialized $9 billion worth of wind and solar projects representing nearly 7 GW of clean energy opportunity.

“XL Fleet and Apex Clean Energy share a common goal of delivering sustainable products and services designed to protect our environment, and we are proud to become Apex’s electrified vehicle partner as they look to take immediate and significant steps toward reducing their carbon footprint,” said Brian Piern, VP of Sales and Marketing at XL Fleet.

“As a mission-driven company with sustainability at the heart of our work, Apex is driving the transition to a clean energy economy, and XL Fleet is an ideal partner to help us extend this core value to our transportation choices,” said Mark Goodwin, president and CEO of Apex Clean Energy. “XL Fleet gives us the ability to begin working toward our carbon reduction goals immediately by electrifying our vehicle fleet with proven solutions that make strong financial sense.”

This deployment of electrified pickups reflects XL Fleet’s broad lineup of plug-in hybrid and hybrid solutions for some of the fleet industry’s most popular light and medium duty work trucks, which also includes the Company’s newest plug-in and hybrid offerings for Chevrolet Silverado and GMC Sierra HD models.

The Ford F-series pickups being electrified for Apex were acquired by XL Fleet’s Fleet Management Company (FMC) partner Enterprise Fleet Management as part of this transaction. Enterprise is a leading full-service provider of fleet management capabilities, including vehicle acquisition, financing, maintenance and more. Enterprise takes a sustainable approach to its business practices and actively helps fleet customers manage their carbon footprint.

About XL Fleet Corp.

XL Fleet is a leading provider of vehicle electrification solutions for commercial and municipal fleets in North America, with more than 150 million miles driven by customers such as The Coca-Cola Company, Verizon, Yale University and the City of Boston. XL Fleet’s hybrid and plug-in hybrid electric drive systems can increase fuel economy up to 25-50 percent and reduce carbon dioxide emissions up to 20-33 percent, decreasing operating costs and meeting sustainability goals while enhancing fleet operations. XL Fleet’s plug-in hybrid electric drive system was named one of TIME magazine’s best inventions of 2019. For additional information, please visit www.xlfleet.com.

About Apex Clean Energy

Apex Clean Energy develops, constructs, and operates utility-scale wind and solar power facilities across North America. Our mission-driven team of more than 250 renewable energy experts uses a data-focused approach and an unrivaled portfolio of projects to create solutions for the world’s most innovative and forward-thinking customers. For more information on how Apex is leading the transition to a clean energy future, visit apexcleanenergy.com or follow us on Facebook, Twitter, and LinkedIn.

Forward Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of management and are not predictions of actual performance. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, including but not limited to failure to realize the anticipated benefits from the business combination; the effects of pending and future legislation; the highly competitive nature of the Company’s business and the commercial vehicle electrification market; litigation, complaints, product liability claims and/or adverse publicity; cost increases or shortages in the components or chassis necessary to support the Company’s products and services; the introduction of new technologies; the impact of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, regulatory compliance and customer experience; the potential loss of certain significant customers; privacy and data protection laws, privacy or data breaches, or the loss of data; general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; the inability to convert its sales opportunity pipeline into binding orders; risks related to the rollout of the Company’s business and the timing of expected business milestones; the effects of competition on the Company’s future business; the availability of capital; and the other risks discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed on March 31, 2021 and other documents that the Company files with the SEC in the future. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. These forward-looking statements speak only as of the date hereof and the Company specifically disclaims any obligation to update these forward-looking statements.

Media:

[email protected]

Investor:

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Transportation Alternative Energy Energy Travel Automotive Trucking General Automotive Transport

MEDIA:

Logo
Logo
Photo
Photo
(Photo: Business Wire)

Origin Materials Adds Key New Technical Hires to Further Strengthen Global Technology Leadership in Carbon Negative Materials

Origin Materials Adds Key New Technical Hires to Further Strengthen Global Technology Leadership in Carbon Negative Materials

Highly skilled veterans bring extensive expertise and experience in industrial chemical engineering, petrochemicals, solids processing, refining and renewable energy

WEST SACRAMENTO, Calif.–(BUSINESS WIRE)–Origin Materials, Inc. (“Origin Materials”), the world’s leading carbon negative materials company, today announced the addition of Mr. Jim Wells, Dr. Ben Freireich, and Dr. Madhu Anand to the company’s technical team.

Origin Materials’ new technical hires will play a key role in leveraging the company’s patented, breakthrough carbon negative platform technology to develop and scale new innovations. Origin Materials believes its technology will help revolutionize the production of a wide range of end products, including clothing, textiles, plastics, packaging, car parts, tires, carpeting, toys and more with a ~1 trillion addressable market.

“I am very pleased to welcome these highly skilled veterans to Origin Materials to further bolster our global technology leadership and capabilities in carbon negative materials,” said John Bissell, Co-Founder and Co-CEO of Origin Materials. “Jim, Ben and Madhu bring deep chemical, energy and solids processing experience to Origin Materials and their technical expertise will play a pivotal role in driving our innovation pipeline to deliver carbon negative solutions to our global customer base across a wide range of product end markets.”

Jim Wells joins Origin Materials as a Technical Director with 39 years of experience in the chemical industry. During his 39-year career at The Dow Chemical Company, Mr. Wells was responsible for developing, designing, building, and starting up industrial chemical plants, leading project teams and developing unique technologies. In January 2018, Mr. Wells retired from Dow as Associate Director of Technology for the Dow AgroScience division. He is a recognized subject matter expert in project management, engineering and manufacturing work processes, reactive chemicals and layer of protection analysis, and solids processing, handling and packaging. Mr. Wells served in the United States Army and graduated from Cornell University with a BS in Chemical Engineering.

Ben Freireich joins Origin Materials as a Technical Fellow with more than a decade of experience in the chemical and process industries. Dr. Freireich comes to Origin Materials as a leading industry expert in both product and process research and development for solid materials. Prior to Origin Materials, Dr. Freireich served as the Technical Director of Particulate Solid Research, Inc. (PSRI) where he led applied process research efforts for a consortium of over thirty multinational corporations. He was previously a Research Scientist in Core R&D at The Dow Chemical Company, where he served as subject matter expert responsible for product and process development over a wide range of businesses, products, and technologies. Dr. Freireich is a specialist in particle technology with expertise in particle design, powder flowability, mixing, fluidization, size enlargement, attrition, and other areas of solids engineering, and has authored chapters of Perry’s Chemical Engineering Handbook. He obtained his PhD in Mechanical Engineering from Purdue University studying manufacturing processes involving solid materials. Dr. Freireich also holds a Master of Science in Engineering from Purdue and graduated from the Milwaukee School of Engineering with a BS in Mechanical Engineering.

Madhu Anand joins Origin Materials as a Technical Director with more than 15 years of experience in the oil and energy industry. Prior to Origin Materials, Dr. Anand held various roles at Phillips 66, most recently serving as Chief Engineer of Hydroprocessing & Naphtha Upgrading, where she played a key role in strategy, technology evaluation and development, product management, joint venture management, and commercial development. Dr. Anand is highly skilled at developing technologies and solving complex problems for the refining, renewables, and petrochemical sectors and is recognized for directing scale-up projects from lab to commercial implementation involving multidisciplinary teams. She completed her PhD in Chemical Engineering from Auburn University, where she received the 2007 Outstanding Graduate Award for excellence in research, and graduated from Panjab University in India with a BS in Chemical Engineering.

About Origin Materials

Headquartered in West Sacramento, Origin Materials is the world’s leading carbon negative materials company. Origin Materials’ mission is to enable the world’s transition to sustainable materials. Over the past 10 years, Origin Materials has developed a platform for turning the carbon found in non-food biomass into useful materials, while capturing carbon in the process. Origin Materials’ patented drop-in core technology, economics and carbon impact have been validated by trusted third parties and are supported by a growing list of major global customers and investors. Origin Materials’ first plant is expected to be operational in 2022 with a second, full-scale commercial plant expected to be operational by 2025 and plans for additional expansion over the next decade.

On February 17, 2021, Origin Materials and Artius Acquisition Inc. (“Artius”) (Nasdaq: AACQU, AACQ), a publicly-traded special purpose acquisition company, announced a definitive agreement for a business combination that will result in Origin Materials becoming a public company. Upon closing of the transaction, expected in the second quarter of 2021, the combined company will be named Origin Materials and remain listed on the Nasdaq under the new ticker symbol “ORGN.” The transaction is expected to fully fund Origin Materials until EBITDA positive, and allows Origin Materials to scale and commence commercial production to meet signed customer offtake and capacity reservations of ~$1 billion across a diverse range of industries.

For more information, visit www.originmaterials.com.

Important Information for Investors and Stockholders

In connection with the proposed business combination transaction, Artius filed a registration statement on Form S-4 (the “Registration Statement”) with the SEC on March 9, 2021, which includes a preliminary proxy statement to be distributed to holders of Artius’s ordinary shares in connection with Artius’s solicitation of proxies for the vote by Artius’s stockholders with respect to the proposed transaction and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of securities to be issued to Artius’s and Origin Materials’ stockholders in connection with the proposed transaction. After the Registration Statement has been declared effective, Artius will mail a definitive proxy statement, when available, to its stockholders. Investors and security holders and other interested parties are urged to read the proxy statement/prospectus, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about Artius, Origin Materials and the proposed transaction. The documents relating to the proposed transaction (when they are available) can be obtained free of charge from the SEC’s website at www.sec.gov. Free copies of these documents, once available, may also be obtained from Artius by directing a request to: Artius Management LLC, 3 Columbus Circle, Suite 2215 New York, New York 10019.

Cautionary Note on Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including with respect to the proposed transaction between Origin Materials and Artius. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Origin Materials’ business strategy, estimated total addressable market, commercial and operating plans, product development plans and projected financial information. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Origin Materials and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Origin Materials and Artius. These forward-looking statements are subject to a number of risks and uncertainties, including that Origin Materials may be unable to successfully commercialize its products; the effects of competition on Origin Materials’ business; the uncertainty of the projected financial information with respect to Origin Materials; disruptions and other impacts to Origin Materials’ business as a result of the COVID-19 pandemic and other global health or economic crises; changes in customer demand; Origin Materials and Artius may be unable to successfully or timely consummate the proposed business combination, including the risk that any regulatory approvals may not obtained, may be delayed or may be subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the business combination, or that the approval of the stockholders of Artius or Origin Materials may not be obtained; failure to realize the anticipated benefits of the business combination; the amount of redemption requests made by Artius’ stockholders, and those factors discussed in the Registration Statement under the heading “Risk Factors,” and other documents Artius has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Origin Materials presently does not know, or that Origin Materials currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Origin Materials’ expectations, plans, or forecasts of future events and views as of the date of this press release. Origin Materials anticipates that subsequent events and developments will cause its assessments to change. However, while Origin Materials may elect to update these forward-looking statements at some point in the future, Origin Materials specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Origin Materials’ assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Participants in the Solicitation

Artius, Origin Materials and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from Artius’s shareholders in connection with the proposed business combination. Information about Artius’s directors and executive officers and their ownership of Artius’s securities is set forth in the Registration Statement described above. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading other documents Artius has filed, or will file, with the SEC regarding the proposed business combination, including the definitive proxy statement when it becomes available.

Non-Solicitation

This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Artius, the combined company or Origin Materials, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Investors:

[email protected]

Media:

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Chemicals/Plastics Other Energy Environment Manufacturing Alternative Energy Energy Other Manufacturing

MEDIA:

Boston Private Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding the Proposed Transaction with SVB Financial

Boston Private Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding the Proposed Transaction with SVB Financial

The SVB Financial Merger Continues To Be Financially and Strategically Compelling

HoldCo’s Proposal Is Reckless, Founded on Flawed Valuation Analyses and Misleading Assertions, and Value Destructive

BOSTON–(BUSINESS WIRE)–
The Board of Directors of Boston Private Financial Holdings, Inc. (NASDAQ: BPFH) (“Boston Private”), a leading provider of integrated wealth management, trust and banking services to individuals, families, businesses and nonprofits, today issued an investor presentation and sent a letter to Boston Private’s shareholders regarding the previously announced definitive merger agreement with SVB Financial Group (NASDAQ: SIVB) (“SVB Financial”). The investor presentation is available at https://ir.bostonprivate.com/files/doc_presentations/2021/04/Investor-Presentation.pdf.

The letter and investor presentation reiterate why the SVB Financial transaction continues to provide the best path for maximizing value for Boston Private shareholders, and respond in detail to HoldCo’s misleading assertions, unsubstantiated analyses and reckless and illusory proposal that threatens to destroy substantial shareholder value.

The Boston Private Board unanimously recommends that shareholders vote on the WHITE proxy card “FOR” the proposed transaction with SVB Financial and “FOR” the other matters to be considered at the April 27, 2021 special meeting.

The full text of the letter from the Board of Directors to shareholders follows.

April 7, 2021

 

Dear Boston Private Shareholders:

 

The special meeting of Boston Private shareholders to approve the value-maximizing transaction with SVB Financial, scheduled for April 27, 2021, is rapidly approaching. 

 

If the merger with SVB Financial is completed, holders will be entitled to receive, for each share of Boston Private common stock owned, $2.10 in cash and 0.0228 shares of SVB Financial common stock, an implied value of $13.12 per share of Boston Private common stock based on the closing stock price of SVB Financial common stock on April 1, 2021, representing a 56% premium to Boston Private’s unaffected share price as of immediately prior to announcement of the transaction.

 

The Boston Private Board of Directors (the “Board”) carefully considered the company’s available alternatives and concluded that the transaction maximizes value for, and is in the best interests of, all Boston Private Shareholders.  The Board unanimously recommends that you vote on the WHITE proxy card “FOR” the proposed transaction with SVB Financial and “FOR” the other matters to be considered at the April 27, 2021 special meeting to approve the transaction.  You can vote by mail, over the Internet or by a toll-free telephone call.  Simply follow the instructions on the attached WHITE proxy card.  We urge you to vote by telephone or over the Internet to ensure your vote is received in time to be counted at the special meeting. 

 

Your vote is very important, regardless of how many shares you own.  The failure to vote your shares or an abstention from voting has the same effect as a vote against the transaction.  The transaction cannot be completed unless the merger agreement is approved by the affirmative vote of at least 66 2/3% of the outstanding shares of Boston Private common stock entitled to vote.

 

You may have received communications from an entity called HoldCo Asset Management, LP (“HoldCo”) seeking your support to defeat the transaction with SVB Financial.  The Board believes that HoldCo’s illusory proposal is a reckless gamble based on arguments without merit that, if successful, would imperil the value of your investment in Boston Private.  

 

Your Board is unanimous in its opposition to HoldCo’s efforts and recommends you ignore their communications and not vote any of their gold proxy cards.  If you have voted on a gold proxy card, please vote FOR the proposed transaction with SVB Financial using a WHITE proxy card.  Only your latest dated vote counts. 

 

THE TRANSACTION MAXIMIZES VALUE FOR BOSTON PRIVATE SHAREHOLDERS

 

The Board believes that the transaction with SVB Financial is a financially and strategically compelling opportunity that maximizes value for, and is in the best interests of, all Boston Private shareholders.

 

Compelling Valuation  

 

Across multiple financial metrics, the merger with SVB Financial represents one of the most financially attractive bank deals in years.

 

As a result of the Board’s negotiating efforts, SVB Financial increased the value of the merger consideration offered from $7.60 per Boston Private share in August 2020 to $10.94 per Boston Private share as of December 31, 2020, the last trading day prior to the date of announcement of the merger agreement.  At the time the transaction was announced, the merger consideration represented the highest price to forward earnings-per-share multiple and second-highest announcement date premium in a major bank transaction in the past three years.1  This already-compelling premium has substantially increased since that time as a result of the appreciation of SVB Financial’s share price, and represents an implied value of $13.12 based on SVB Financial’s closing price on April 1, 2021, corresponding to a 56% premium to Boston Private’s unaffected share price as of immediately prior to announcement of the transaction and a 21.2x price to forward earnings-per-share multiple.2  The Board believes that the transaction with SVB Financial provides substantially higher and more certain value to Boston Private shareholders than the company’s available alternatives.      

 

The Right Partnership 

 

SVB Financial is the right partner for Boston Private, which will further benefit current Boston Private shareholders once the merger is completed.  It has a differentiated platform with a long track record of stellar execution and industry-leading growth, all of which will be enhanced by the capabilities of the combined company to leverage SVB Financial’s balance sheet, expansive client network and position at the center of the innovation economy to augment Boston Private’s wealth management solutions and accelerate value creation opportunities for Boston Private shareholders.  Not only does the merger with SVB Financial provide significant immediate financial benefits to Boston Private shareholders through a compelling premium, the Boston Private Board believes that the transaction will enable shareholders to benefit from the strategic merits of the combination by participating in the upside potential of the combined company, and is the clear long-term value maximizing alternative for shareholders.      

 

The Right Timing 

 

The Board’s decision to capitalize on a compelling strategic opportunity with SVB Financial and lock-in a fixed exchange ratio when it did has already generated hundreds of millions of dollars in incremental value for Boston Private shareholders above and beyond the almost 30% premium already embedded in the implied value of the merger consideration at the time of announcement of the transaction.  As described in detail below, delaying negotiations with SVB Financial in order to pursue discussions with other potential counterparties, as HoldCo has proposed, would have wiped away hundreds of millions of dollars in value for Boston Private shareholders, while providing no discernible benefits and significantly increasing various risks, including the potential loss of the SVB Financial deal altogether.  The timing of the transaction was critical to capturing the upside potential in the price of SVB Financial common stock based on SVB Financial’s continued strong performance.       

 

The Right Process

 

Independent Board Conducted Extensive Analysis and Carefully Considered All Available Alternatives

 

In 11 meetings over the course of several months, the Board assessed the company’s standalone plan and the opportunities, risks and challenges associated with that plan, and analyzed with its financial advisor the universe of alternative potential strategic merger partners and the several inbound inquiries it received.  The Board was very familiar with the strategic merits of those potential partners as well as the merger consideration they would potentially be able to offer as the result of the Board’s and its’ advisors’ significant corporate advisory, banking and financial services experience, and deep industry knowledge.  Accordingly, the Board determined that:

  • no potential merger partner would be a better strategic fit or offer more favorable terms or stronger prospects for future growth and value creation to Boston Private shareholders than SVB Financial; and
  • the transaction with SVB Financial would provide more value, sooner, with significantly more certainty and significantly less execution risk, than the company’s standalone plan, while at the same time offering participation in the long-term growth potential of the combined company at a level that was unlikely to be achieved under the standalone plan.

The Board’s Process Maximized Value Without the Risks Inherent in an Auction

 

HoldCo repeatedly asserts that the company referred to in Boston Private’s definitive proxy statement as Company A “was offering a higher price than SVB was offering at that time.”  This is simply false.  Neither Company A nor any other party — other than SVB Financial — made any offer or proposal to acquire Boston Private, either during the negotiation process with SVB Financial or at any time since announcement of the transaction.  HoldCo’s distortions underscore its inability to engage with real-world facts.  Having no on-the-ground experience with bank M&A processes, HoldCo subscribes to a black-and-white, purely theoretical philosophy by which auctions must automatically lead to the best outcome for shareholders.  But the transaction process implemented by the Board was not an academic exercise undertaken in an ivory tower — it was a real-world negotiation carefully designed and calibrated with the advice of expert advisors to maximize value for Boston Private shareholders.  In the real-world, the tone of a conversation matters, timing matters and reasoned and experienced assessments of a potential acquiror’s preparation, seriousness and ability to pay matter. 

 

These nuances are lost on HoldCo, but they are reflected in precedent bank transactions, where a majority of target companies do not undertake auction processes, and where auction processes generally do not produce better results than bilateral negotiations.3  The reasons are simple:  the universe of potential strategic buyers for banks of Boston Private’s size is limited and well-known to those in the industry; to the extent that any such potential buyers are interested in a strategic combination, they typically make their interest known to targets proactively; and for a business whose principal assets — its people — walk out the door at the end of every business day, the risks of running a broad auction process and exposing the company to potential leaks, market rumors and resulting employee and customer attrition are real and need to be weighed against the hypothetical and, in many cases, illusory benefits of running such a process.   

 

Yet HoldCo would apparently have Boston Private open up its books and provide highly confidential and competitively sensitive diligence materials and access to employee and customer information to any competitor that expresses even the slightest interest in discussing a possible transaction, no matter how vague, soft or flimsy their overtures or terms might be.  The Board disagrees with that philosophy. 

 

A review of the inquiries from HoldCo’s three purported potential buyers confirms that there was no credible reason for Boston Private to affirmatively pursue further discussions with any of these parties, and that the Board chose the value-maximizing process.  

 
  • Company A:  Notwithstanding HoldCo’s mischaracterizations, Company A never made any proposal to acquire Boston Private.  Instead, it approached Boston Private casually based on speculation that Boston Private might already be considering a strategic business combination and indicated that, subject to numerous contingencies, it might consider a valuation at a tangible book value multiple in a general price range of $10.50.  Company A never submitted any letter, indication of interest or other written expression of interest, nor did it propose any specific transaction terms, or indicate whether an actual proposal was expected to be discussed with or approved by its board of directors.  The Board discussed and considered Company A’s outreach and determined that it was highly speculative and contingent.  The Board also concluded that there was greater upside potential in SVB Financial’s stock price, and therefore in the value of the merger consideration, that would not apply to Company A even if it were to submit an actionable proposal at or around its indicated potential valuation level.  After considering all the facts, the Board concluded that Company A was unlikely to (i) be a better strategic fit for Boston Private than SVB Financial, (ii) offer terms more favorable to Boston Private’s shareholders than those offered by SVB Financial, or (iii) offer better prospects for future growth and value accretion for the benefit of Boston Private’s shareholders.
  • September 2020 Inquiry:  HoldCo criticizes Boston Private for not inviting another party that inquired about a transaction in September 2020 to participate in an auction process.  As previously disclosed, this party inquired about a transaction at a 20-25% premium to Boston Private’s then-current stock price, which was in the range of $5.50 per share, implying a transaction value of around $6.60 – $6.87 per share.  At that time, discussions with SVB Financial centered around SVB Financial making a proposal valuing Boston Private at approximately $9.25 per share, which the Boston Private Board concluded was still an inadequate price.  There was simply no reason for Boston Private to waste time, money and effort, or magnify the attendant confidentiality, competitive, employee and customer retention risks, by engaging on an inquiry with such an inferior value proposition.
  • Similarly-Sized California-Based Bank Holding Company:  Finally, HoldCo suggests that Boston Private should have engaged in transaction negotiations with a California-based bank holding company of similar size to Boston Private.  As previously disclosed, in 2019 Boston Private engaged in preliminary discussions with representatives of this potential counterparty, which centered around an acquisition by Boston Private of this counterparty — a completely different transaction than the SVB Financial merger (or, for that matter, any sale transaction advocated by HoldCo), in which Boston Private would be paying a premium, instead of receiving one.  Boston Private had previously determined that such a transaction would not be financially attractive or create meaningful value for Boston Private shareholders, and that this company was not a strong financial, cultural or strategic fit for Boston Private.  Accordingly, there was no reason to engage in further discussions with this potential counterparty.  HoldCo’s contention that inviting this party — whose apparent interest was in being acquired by Boston Private — to participate in an auction to acquire Boston Private would have somehow generated competitive pressure and resulted in SVB Financial delivering additional merger consideration defies logic, and further underscores HoldCo’s lack of understanding of real-world negotiating dynamics.

Far from lending support to HoldCo’s auction theory, what these various informal inquiries actually show is that the Board was extremely well-informed regarding the pool of potential strategic counterparties that might be interested in pursuing a strategic combination and the level of consideration that they might be able and willing to offer.  If any of the parties that HoldCo asserts would have offered superior financial terms, or indeed any other potential strategic partner, were in fact interested in and capable of acquiring Boston Private at a premium valuation relative to the merger with SVB Financial, they would have submitted a proposal.  None did.

 

Contrary to HoldCo’s monolithic view of M&A processes, the Board does not believe that there is any single blueprint for how to achieve the best result in selling a company.  It is a fact- and context-specific determination that requires careful consideration and evaluation of a number of factors that bear on the risks and benefits of approaching additional parties or instead pursuing a transaction with a company that has made a compelling strategic offer.  The Board ran a robust, thorough and value-maximizing process for Boston Private shareholders and successfully secured one of the highest premia of any bank merger in years, and locked-in an exchange ratio at a time that has allowed Boston Private shareholders to benefit from the substantial upside in SVB Financial’s stock price. 

 

HOLDCO’S PATH FORWARD IS RECKLESS, NOT VIABLE AND EXPOSES BOSTON PRIVATE SHAREHOLDERS TO SIGNIFICANT RISKS

 

While the Board has provided a value-maximizing transaction with a compelling premium and significant long-term upside prospects, HoldCo lacks any coherent strategy or viable value proposition for Boston Private shareholders, and its proposed “path forward” is illusory and would expose you to major risks.

 

It is clear that prior to the announcement of the SVB transaction, HoldCo was planning to launch a proxy fight against the Board and advocate for a sale of the company.  But before HoldCo could do so, the Board capitalized on the opportunity with SVB Financial, delivering a strategic transaction at a price that maximizes value for Boston Private shareholders.  The Board preempted HoldCo’s platform by doing what was right for Boston Private shareholders and acting at the right time, but HoldCo is determined to move forward with its contest anyway.

 

The result is a “path forward” that is reckless, unrealistic and lacks any feasible means of delivering additional value.  Notwithstanding HoldCo’s claims that the steps to achieving enhanced value are “simple and straightforward,” they are in fact fraught with risk.     

 

HoldCo’s Proposed Sale Process Threatens To Expose Boston Private to Uncapped Damages

 

HoldCo continues to propose that Boston Private “commence a competitive [sale] process immediately.”  But as the Board noted in its prior communication to shareholders, commencing such a process would be a willful breach of Boston Private’s obligations under the merger agreement with SVB Financial, an inconvenient fact that HoldCo knows, or should know if it had in fact read the publicly available merger agreement, but has blatantly ignored in all of its communications to you.  HoldCo is either attempting to deliberately mislead you or is willing to expose your company to uncapped potential damages. 

 

HoldCo’s proposed path forward is a fantasy, and entirely illusory.  Unless the parties mutually agree to terminate the merger agreement, until the January 3, 2022 termination date is reached or another termination event occurs, neither party can abandon the transaction and each must use reasonable best efforts to complete the merger.

 

HoldCo’s Expectations of Potential Acquirors Are Unrealistic and Unsupported

 

HoldCo has now implicitlyacknowledged that a previously unknown mystery acquiror is not likely to materialize.  As such, HoldCo is pinning its hopes on a limited universe of potential acquirors, several of whom made informal and preliminary inquiries of Boston Private that the Board carefully evaluated and, as discussed above, determined (correctly) were unlikely to result in terms more favorable to Boston Private shareholders than those offered by SVB Financial.  HoldCo has not demonstrated why any of those parties, or for that matter any other potential acquiror, would suddenly be likely to make a proposal to acquire Boston Private, much less one that delivers more value than the transaction with SVB Financial.  To date, no such proposal has been made.  HoldCo may be comfortable taking a flyer on the unlikely possibility of such a proposal emerging; the Board is not.       

 

Proposed Slash and Burn Approach Would Destroy Value

 

Perhaps understanding that re-initiating a sales process is not feasible and that there is no mystery acquiror waiting in the wings, HoldCo has pivoted to proposing vague operational changes that amount to nothing more than a slash and burn approach designed to artificially boost short-term share price performance through excessive cost cutting and return of capital, to the detriment of the long-term value of the Boston Private franchise.  HoldCo’s analysis, resting on faulty and unsubstantiated assumptions, would fail to deliver value to Boston Private shareholders on par with the SVB Financial merger consideration even in the short term and likely result in significant customer and employee attrition and irredeemable damage to the Boston Private business.  To make its plan appear to create value, HoldCo makes a series of groundless assumptions, including establishing cost-savings by reference to a set of peers with very different business models, assuming multiple expansion solely as a result of cost-cutting, and, most egregiously, assuming that the company could buy back $115 million of its shares at $10 while bumping its share price to more than $17 — an assumption both absurd on its face and that would raise serious questions under the federal securities laws. 

 

HoldCo’s standalone “plan,” which might as well have been sketched out on the back of a napkin, further illustrates the dangers of delegating the strategy for ongoing operations of Boston Private and its subsidiaries to HoldCo.  This slash and burn approach that fails to deliver value in the short term while destroying Boston Private’s long-term prospects stands in stark contrast to the compelling value, upside participation and certainty of execution that the SVB Financial transaction will deliver for Boston Private shareholders.

 

HoldCo’s Withdrawal of Its Own Nominees Demonstrates a Lack of Commitment and the Absence of a Coherent Strategy

 

As the Board previously noted, HoldCo was forced to withdraw its nomination notice with respect to two of its nominees to the Boston Private Board — HoldCo’s own co-founders Michael Zaitzeff and Vikaran Ghei — due to its parallel threatened proxy fight against another Boston-based bank holding company, Berkshire Hills Bancorp, Inc., where it also nominated Mr. Zaitzeff to the board of directors.  That HoldCo consciously decided to forego the possibility of nominating a majority slate that included HoldCo’s founders to the Boston Private Board in favor of having a single representative on the Berkshire board demonstrates HoldCo’s utter lack of conviction in the strength of its arguments or its likelihood of success.  Moreover, it confirms that HoldCo does not have a coherent strategy.  It has a bag of risky, half-baked proposals and no idea how to execute on them.  Even if HoldCo’s three unaffiliated nominees were elected to the Board and adopted HoldCo’s agenda, they would constitute only a minority of the Board and would have no mechanism to cause Boston Private to pursue HoldCo’s ill-advised and risky gambles, and given HoldCo’s board seat at Berkshire Hills, a competing bank operating in the same market as Boston Private, it is far from clear that HoldCo would even be able to actively participate, directly or indirectly, in key strategic decisions of the Boston Private Board given antitrust, bank regulatory and confidentiality considerations. 

 

Though HoldCo has not articulated a feasible “path forward,” all of its proposed roads lead to the same dead end:  giving up a compelling transaction with certainty of value and significant upside in favor of a collection of reckless gambles, each with substantial and readily apparent risks, and highly theoretical and illusory potential benefits. 

 

HOLDCO’S MISGUIDED ATTACKS AND BASELESS ASSUMPTIONS ARE NO SUBSTITUTE FOR THE BOARD’S INFORMED VALUATION ANALYSES

 

In considering the SVB Financial transaction, the Board and its advisors carefully evaluated Boston Private’s standalone plan and the valuation it implied, and determined that the SVB Financial transaction would deliver more value, sooner, with significantly more certainty and significantly less execution risk than the company’s standalone plan.  

 

In contrast, Holdco has not undertaken any serious valuation analyses or engagement with Boston Private’s standalone plan, and has made no attempt to defend its naive “sum of the parts” and “contribution” analyses — methodologies that are inapplicable to Boston Private’s business or the transaction at hand, include numerous flawed assumptions and ignore fundamental valuation principles.  Instead of defending its analyses, HoldCo has resorted to attacking the market’s valuation of SVB Financial, using sleights of hand and pretending the world did not change as a result of the pandemic. 

 

Attacks Against SVB Financial Are Misguided

 

HoldCo presents several purported analyses that, while framed in different ways, boil down to a single assertion:  HoldCo believes that the market is ascribing too much value to SVB Financial’s shares, and that it knows better than the market.   

 

HoldCo’s attacks against SVB Financial have no basis in reality.  As industry analysts recognize, SVB Financial has a differentiated platform with exceptional growth opportunities in key industries, along with a history of operational excellence and credit quality that leaves little doubt about its ability to successfully capitalize on these opportunities.  SVB Financial’s premium valuation is not a short-term blip — it is based on a long-term track record of successful execution:  over the last ten years, SVB Financial has significantly outperformed its peers on almost every key metric.  Accordingly, each of SVB Financial’s 1-, 3-, 5- and 10-year total shareholder returns far outpace its peers and banks generally.4 The market again validated SVB Financial’s premium valuation just two weeks ago, as SVB Financial successfully raised $1 billion in a common stock offering from major institutional investors in a single day at a price of $500 per share, implying a price-to-earnings multiple of 24.4x.5

 

HoldCo’s attacks on SVB Financial fly in the face of what the rest of the market already knows, has known for years and has very recently validated — that SVB Financial’s unique position at the center of the innovation economy, fundamentally different balance sheet and earnings growth opportunities and outstanding record of performance justify its premium multiple.

 

HoldCo Is Living in a Pre-Pandemic World   

 

HoldCo attempts to undermine the compelling value created by the SVB Financial transaction by comparing the value of the merger consideration to Boston Private’s pre-pandemic share price and referencing the parties’ pre-pandemic performance.  These comparisons are irrelevant, out of touch with reality and fail to take into account the significant changes in interest rates, the competitive environment and the businesses and growth prospects of Boston Private, SVB Financial and their respective clients arising out of the pandemic and ongoing recovery.  HoldCo is living in the past and focused on pre-pandemic performance and share prices.  The Board, on the other hand, is focused on maximizing value for Boston Private shareholders in the present and over the long-term — the Board evaluated Boston Private’s future prospects in light of a changing environment and determined that the transaction with SVB Financial was the best way to maximize value.

 

Sleights of Hand Reinforce HoldCo’s Mistakes

 

HoldCo’s attempt to reframe the transaction consideration in terms of exchange ratio rather than value is not only incorrect, it repeats the same mistakes that HoldCo made in its valuation analyses and highlights how a process managed by HoldCo would have produced inferior results.  HoldCo’s assertions that the Board “ineptly negotiated for lower consideration as the process with SVB unfolded” and that SVB Financial’s final offer represented a 22% decline in value are blatantly false.  The Board negotiated to increase the value of the merger consideration from approximately $7.60 per Boston Private share to $10.94 per Boston Private share at the date of announcement of the transaction, a value reflecting the second-highest premium in a major bank transaction in the last three years.  HoldCo’s attempted sleight of hand again ignores the differing valuation and growth profiles of Boston Private and SVB Financial and the resulting possibility that their share prices would change at differing rates over time, while naively assuming that SVB Financial (or any other potential acquiror) would intentionally undervalue itself by negotiating a transaction without regard for positive changes to its own valuation and growth prospects. 

 

And yet, the increase in SVB Financial’s stock price, the very issue about which HoldCo complains, would have been greatly exacerbated by HoldCo’s suggestion that Boston Private invite other parties into an auction process to somehow “keep SVB honest” about the market value of SVB Financial’s shares.  As HoldCo would have it, Boston Private would have been mired in an auction process with bidders the Board deemed unlikely to be competitive and, as a result, would have missed its window to capture the potential appreciation in the value of SVB Financial shares for the benefit of Boston Private shareholders.  Had Boston Private sought to prolong negotiations with SVB Financial in order to run an auction process, not only would Boston Private have risked losing the SVB Financial transaction altogether, particularly in light of SVB Financial’s final proposal being expressly conditioned on exclusivity, but even if a transaction had materialized based on the ultimately agreed pricing it would have cost Boston Private shareholders approximately $240 million in aggregate consideration value.6  It was precisely those risks, along with the significant risks to the Boston Private franchise from a confidentiality, competitive, and employee and customer retention perspective, that the Board carefully weighed against the potential benefits of rejecting or attempting to delay SVB Financial’s final proposal and pursuing discussions with other potential strategic parties.  The Board correctly concluded that those risks far outweighed any conceivable benefits of delay.  

 

THE BOARD RAN AN EXEMPLARY PROCESS DELIBERATELY SEQUENCED TO AVOID POTENTIAL CONFLICTS

 

The Board’s thoughtful sequencing of the negotiations with SVB Financial avoided conflicts to ensure a result that maximized value for Boston Private shareholders.  HoldCo’s continued efforts to falsely paint the transaction with SVB Financial as a conflict-ridden, management-friendly deal have no basis in fact, do not hold up to even the most cursory level of scrutiny, and are a desperate attempt to gain traction where all substantive arguments have failed.

 

The Board Ran a Model Process

 

The Board ran a thorough, independent-director-driven process that was deliberately sequenced to ensure that any negotiations between Mr. DeChellis or other members of management and SVB Financial related to post-closing employment or retention arrangements occurred only after negotiations regarding the amount of the merger consideration and the other material transaction terms had been finalized.  All members of the Boston Private Board other than Mr. DeChellis are fully independent, and the Board is comprised of a sophisticated and diverse group of directors with decades of collective financial services experience.  Negotiations were led by a working group comprised of Mr. DeChellis and two independent directors with deep M&A and transactional experience.  The Board’s independent Chair, Stephen Waters, was intimately involved in the key pricing negotiations with SVB Financial, all of which took place more than a month before SVB Financial first provided a term sheet to Mr. DeChellis outlining the proposed terms for his continued employment following completion of the merger.  And the entire Board was fully involved in overseeing the transaction process from start to finish. 

 

For the Board to have formed a special committee to negotiate the transaction, as suggested by HoldCo, would have been both unusual and value destructive.  Special committees are extremely rare — they have been used by target boards in just 6% of major bank transactions over the past ten years7 — and are appropriate where there is a true board conflict that cannot otherwise effectively be mitigated, such as a transaction in which a controlling shareholder stands on both sides of a deal or conflicted directors have a special material interest in the transaction.  That was definitively not the case with respect to Boston Private’s arm’s-length, third party merger negotiations with SVB Financial.  Given the sequencing of the negotiations and the composition of the working group, the formation of a special committee would have done nothing to mitigate any purported “conflict.”  Instead, it would have deprived Boston Private of Mr. DeChellis’s operational expertise during negotiations, which was crucial in demonstrating the value of the company and its wealth management franchise to SVB Financial.  A transaction of the strategic importance of the SVB Financial merger demands the careful review and consideration of all directors and should, in the Board’s view, remain squarely within the ultimate province of the full Board, which is exactly what occurred.

 

Further, HoldCo’s contention that the prospect of continued post-closing employment for Mr. DeChellis represented an “irreconcilable conflict of interest” is based on the false premise that Mr. DeChellis was likely to receive better post-closing employment terms from SVB Financial than from any other potential buyer.  HoldCo’s misleading characterizations rely on stale information, make apples-to-oranges comparisons of target to actual compensation levels, and fail to acknowledge Mr. DeChellis’s waiver of termination protections and forfeiture of Boston Private equity awards. The fact is, Mr. DeChellis received from SVB Financial post-closing employment arrangements on customary and reasonable terms, in a strategic transaction where his ongoing involvement in Boston Private’s wealth management business is an important value driver. 

 

Those arrangements are not unique to the SVB Financial transaction — every other hypothetical acquiror cited by HoldCo would have also acquired Boston Private in a strategic transaction where Boston Private’s wealth management business would have been an important value driver, and so would have wanted to hire Mr. DeChellis.  In fact, as disclosed in Boston Private’s definitive proxy statement, in September 2020, one such potential party had expressed interest in hiring away Mr. DeChellis to run its wealth management business apart from an acquisition, which Mr. DeChellis declined.  Mr. DeChellis had no reason to believe that the package offered by SVB Financial would be any better than that offered by any other possible merger partner, and therefore would have had no reason to direct the transaction toward SVB Financial instead of another merger partner.  HoldCo’s contention that there was an “irreconcilable conflict of interest” is wrong, and the Board carefully designed a process to ensure that no such conflict could arise.      

HoldCo’s Assertions Regarding Retention Arrangements Are False

 

In an even more brazen attempt to mislead you, HoldCo falsely asserts that the one-time merger costs expected to be incurred by SVB Financial “represent a direct transfer of wealth from BPFH shareholders to BPFH executives.”  In reality, SVB Financial has offered BPFH executives customary (and for a transaction of this size, relatively modest) retention awards with aggregate value of up to $7.5 million, roughly 3.5% of SVB Financial’s total assumed restructuring costs and undoubtedly similar to what any other acquiror of Boston Private would have offered to ensure continued performance of Boston Private’s franchise.  These retention arrangements were put in place only after the merger was announced and the pricing and other transaction terms were agreed, and are appropriately structured for retentive purposes — executives will not receive their full retention amounts unless they remain employed with SVB Financial for a full four years after completion of the merger. 

 

Most importantly, there is no basis for HoldCo’s assertion that these retention costs, or for that matter any restructuring charges to be incurred by SVB Financial in connection with the transaction, somehow reduced the amount of the merger consideration payable to Boston Private shareholders, which was negotiated more than a month before SVB Financial put any retention arrangements in place or finalized its due diligence and preliminary restructuring cost analysis.   

 

*****

In sum, the Board believes that the transaction with SVB Financial is a financially and strategically compelling opportunity and is the value-maximizing alternative for all Boston Private shareholders.  In contrast, HoldCo’s proposed path forward is an ever-changing assortment of reckless gambles based upon an indefensible valuation and supported only by misleading assertions and unsubstantiated attacks.  The Board believes that betting the future of Boston Private on HoldCo’s illusory proposal is a risk that is simply too grave to tolerate.   

 

For these reasons, and the reasons set out in greater detail in Boston Private’s definitive proxy statement mailed to shareholders and its other materials filed with the SEC, the Board unanimously recommends that you vote on the WHITE proxy card “FOR” the proposed transaction with SVB Financial and “FOR” the other matters to be considered at the special meeting. 

 

Your vote is very important, regardless of how many shares you own.  The failure to vote your shares or an abstention from voting has the same effect as a vote against the transaction.  The transaction cannot be completed unless the merger agreement is approved by the affirmative vote of at least 66 2/3% of the outstanding shares of Boston Private common stock entitled to vote.

 

If you have any questions or need assistance voting your shares, please contact Innisfree M&A Incorporated, Boston Private’s proxy solicitor, by calling toll-free at (877) 800-5187, or for banks and brokers, collect at (212) 750-5833.

 

On behalf of the Boston Private Board, thank you for your continued support of Boston Private.

 

Sincerely,

 

The Boston Private Board

About Boston Private

Boston Private is a leading provider of integrated wealth management, trust and banking services to individuals, families, businesses and nonprofits. For more than 30 years, Boston Private has delivered comprehensive advice coupled with deep technical expertise to help clients simplify their lives and achieve their goals. The firm offers the capabilities of a large institution with the superior service of a boutique firm to clients across the United States. Boston Private is the corporate brand of Boston Private Financial Holdings, Inc. (NASDAQ: BPFH). For more information, visit www.bostonprivate.com.

Advisors

Wachtell, Lipton, Rosen & Katz is serving as legal counsel to Boston Private and Morgan Stanley & Co. LLC is acting as financial advisor to Boston Private.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to SVB Financial’s and/or Boston Private’s expectations or predictions of future financial or business performance or conditions. Forward-looking statements are typically identified by words such as “believe,” “expect,” “anticipate,” “intend,” “target,” “estimate,” “continue,” “positions,” “prospects” or “potential,” by future conditional verbs such as “will,” “would,” “should,” “could” or “may,” or by variations of such words or by similar expressions. These forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and we assume no duty to update forward-looking statements. Actual results may differ materially from current projections. In addition to factors previously disclosed in SVB Financial’s and Boston Private’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: ability to obtain regulatory approvals and meet other closing conditions to the merger, including approval by Boston Private’s shareholders on the expected terms and schedule; delay in closing the merger; the outcome of any legal proceedings that have been or may be instituted against SVB Financial or Boston Private; the occurrence of any event, change or other circumstance that could give rise to the right of one or both parties to terminate the merger agreement providing for the merger; difficulties and delays in integrating Boston Private’s business or fully realizing cost savings and other benefits; business disruption following the merger; changes in asset quality and credit risk; the inability to sustain revenue and earnings growth; the inability to retain existing Boston Private clients; the inability to retain Boston Private employees; changes in interest rates and capital markets; inflation; customer borrowing, repayment, investment and deposit practices; customer disintermediation; the introduction, withdrawal, success and timing of business initiatives; competitive conditions; the inability to realize cost savings or revenues or to implement integration plans and other consequences associated with mergers, acquisitions and divestitures; economic conditions; the impact, extent and timing of technological changes, capital management activities, and other actions of the Federal Reserve Board and legislative and regulatory actions and reforms; and the impact of the global COVID-19 pandemic on SVB Financial’s and/or Boston Private’s businesses, the ability to complete the proposed merger and/or any of the other foregoing risks. Annualized, pro forma, projected and estimated numbers are used for illustrative purpose only, are not forecasts and may not reflect actual results.

Important Additional Information and Where to Find It

In connection with the proposed merger, SVB Financial has filed with the SEC a registration statement on Form S-4 that includes the proxy statement of Boston Private and a prospectus of SVB Financial. The registration statement on Form S-4, as amended, was declared effective by the SEC on March 17, 2021, and Boston Private commenced mailing of the definitive proxy statement/prospectus to its shareholders on or about March 19, 2021. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. INVESTORS AND SHAREHOLDERS OF BOSTON PRIVATE ARE URGED TO READ THE REGISTRATION STATEMENT AND THE DEFINITIVE PROXY STATEMENT/PROSPECTUS REGARDING THE MERGER AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY CONTAIN IMPORTANT INFORMATION.

A free copy of the definitive proxy statement/prospectus, as well as other filings containing information about SVB Financial and Boston Private, may be obtained at the SEC’s Internet site (http://www.sec.gov). Copies of documents filed with the SEC by SVB Financial will be made available free of charge on SVB Financial’s website at http://ir.svb.com or by contacting SVB Financial’s Investor Relations department at 408.654.7400; 3005 Tasman Drive, Santa Clara, CA 95054; or [email protected]. Copies of documents filed with the SEC by Boston Private will be made available free of charge on Boston Private’s website at http://ir.bostonprivate.com or by contacting Boston Private’s Investor Relations department at 617.912.4386; 10 Post Office Square, Boston, MA 02109; or [email protected].

Participants in the Solicitation

SVB Financial, Boston Private and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Boston Private in connection with the proposed merger. Information about the directors and executive officers of SVB Financial is set forth in the proxy statement for SVB Financial’s 2021 Annual Meeting of Stockholders, which was filed with the SEC on March 4, 2021, and other documents filed by SVB Financial with the SEC. Information about the directors and executive officers of Boston Private is set forth in Boston Private’s Form 10-K for the year ended December 31, 2020, as amended, and other documents filed by Boston Private with the SEC. Additional information regarding the interests of those participants and other persons who may be deemed participants in the transaction may be obtained by reading the definitive proxy statement/prospectus regarding the proposed merger. Free copies of this document may be obtained as described in the preceding paragraph.

_______________________

1 Bank transactions in excess of $500 million since January 1, 2018.

2 Based on equity research consensus 2021 earnings per share estimates of $0.62 per share as disclosed in Boston Private’s definitive proxy statement.

3 Bank transactions in excess of $500 million since January 1, 2018.

4 As of April 1, 2021. SVB Financial 1-year, 3-year, 5-year and 10-year total shareholder return (“TSR”) of 245%, 101%, 369% and 742%, as compared to peers’ TSR of 127%, 18%, 124% and 198% and median of the KBW Nasdaq Bank Index TSR of 114%, 21%, 105% and 181% over the same periods. Peers based on Morgan Stanley fairness opinion analysis, other than People’s United Financial, Inc., where trading has been disrupted by the announced sale to M&T Bank Corporation.

5 Based on estimated 2021 earnings per share of $20.52 per Thomson Reuters median street estimates as of March 22, 2021, following SVB Financial’s Form 8-K providing updated guidance.

6 Applying the agreed-upon pricing formula 30 trading days later would have yielded an exchange ratio of 0.0168x and a current implied value of the merger consideration of $10.22 per share, or approximately $840 million, as compared to the actual current implied value of the merger consideration of $13.12 per share, or approximately $1.08 billion, in each case based on SVB Financial’s closing price on April 1, 2021.

7 FactSet data as of March 31, 2021 for bank transactions in excess of $500 million since January 1, 2010.

Investor Relations

Adam Bromley

(617) 912-4386

[email protected]

Media

Lucy Muscarella

(617) 912-4402

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo